

On page 35, at the end of line 3, after "AGC", please insert --(SEQ ID NO:28)--.

On page 35, at the end of line 5, please insert --(SEQ ID NO:29)--.

On page 35, at the end of line 6, please insert --(SEQ ID NO:30)--.

On page 35, at the end of line 7, please insert --(SEQ ID NO:31)--.

On page 35, at the end of line 8, please insert --(SEQ ID NO:32)--.

On page 35, at the end of line 9, please insert --(SEQ ID NO:33)--.

At page 43, line 3, delete "homogenous" and insert --homogeneous--.

Please delete pages 47-56 and insert the attached Sequence Listing (pages 47-60) and renumber the subsequent pages in the specification accordingly.

### REMARKS


Pursuant to a telephone conference, a substitute specification and a copy of the Sequence Listing filed in application serial no. 08/389,423 are enclosed. The specification also has been amended to correct typographical errors and to provide SEQ ID NOS for the sequences disclosed therein. This submission contains no new matter.

It is respectfully submitted that the present amendment places this case in condition for allowance. Early action to that end is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: April 24, 2000



Elias J. Lambiris, Reg. No. 33,728  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6200  
New York, NY 10174-6201  
(212) 867-0123